Heather McSharry Biography and Net Worth

Director of Jazz Pharmaceuticals

Heather Ann McSharry brings a wide variety of operational expertise to Jazz’s board. With extensive experience with healthcare companies, Ms. McSharry also served as a director for a food manufacturer, an international building materials company, and a home and hygiene consumer products company. This diversity enhances her ability to bring fresh perspectives while also demonstrating her ability to add value in varied situations.

Ms. McSharry has served as a member of our board of directors since May 2013 and was appointed as chairperson of our Nominating and Corporate Governance Committee in August 2017. Ms. McSharry currently serves as a non-executive director on the board of directors of the International Airlines Group (IAG). From 2006 to 2009, Ms. McSharry was Managing Director Ireland of Reckitt Benckiser, a multinational health, home and hygiene consumer products company. From 1989 to 2006, she held various positions at Boots Healthcare, a leading global consumer healthcare company, most recently as Managing Director of Boots Healthcare Ireland Limited. Ms. McSharry served on the board of directors of the Bank of Ireland from 2007 to 2011, where she helped the Bank navigate one of the world’s greatest financial crises. She also served on the boards of directors of the Industrial Development Agency in Ireland from 2010 to 2014, Uniphar plc from 2019 to 2020, CRH plc from 2012 to 2021 and Greencore Group plc from 2013 to 2021. Ms. McSharry holds a Bachelor of Commerce and a Master of Business Studies degree from University College Dublin.

What is Heather Ann McSharry's net worth?: The estimated net worth of Heather Ann McSharry is at least $3.37 million as of November 20th, 2025. Mr. McSharry owns 20,449 shares of Jazz Pharmaceuticals stock worth more than $3,372,245 as of December 18th. This net worth evaluation does not reflect any other investments that Mr. McSharry may own. Learn More about Heather Ann McSharry's net worth.
How do I contact Heather Ann McSharry?: The corporate mailing address for Mr. McSharry and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Heather Ann McSharry's contact information.
Has Heather Ann McSharry been buying or selling shares of Jazz Pharmaceuticals?: Over the course of the past ninety days, Heather Ann McSharry has sold $607,118.70 in Jazz Pharmaceuticals stock. Most recently, Heather Ann Mcsharry sold 3,415 shares of the business's stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $177.78, for a transaction totalling $607,118.70. Following the completion of the sale, the director now directly owns 20,449 shares of the company's stock, valued at $3,635,423.22. Learn More on Heather Ann McSharry's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Heather McSharry (Director), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 2 times. They purchased a total of 101,621 shares worth more than $9,992,963.00. During the last year, insiders at the specialty pharmaceutical company sold shares 23 times. They sold a total of 168,027 shares worth more than $28,003,509.65. The most recent insider tranaction occured on December, 9th when SVP Mary Elizabeth Henderson sold 2,238 shares worth more than $379,363.38. Insiders at Jazz Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 12/9/2025.

Heather Ann McSharry Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/20/2025	Sell	3,415	$177.78	$607,118.70	20,449
5/16/2016	Sell	697	$145.20	$101,204.40	5,396

Heather Ann McSharry Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $166.00

$164.39

$166.67

50 Day Range

MA: $152.76

$131.16

$180.90

2 Week Range

Now: $166.00

$95.49

$182.99

Volume

1,191,454 shs

Average Volume

957,793 shs

Market Capitalization

$10.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3